Business Context and Reporting Period
Company: ENDRA Life Sciences Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2020
Reporting Period: Event date January 13, 2020; Press release issued January 15, 2020.
Context: The Company is an emerging growth company focused on medical technology, specifically its Thermo-Acoustic Enhanced Ultrasound technology for fatty liver disease applications.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a material definitive agreement and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the execution of Amendment 3 to the Collaborative Research Agreement with General Electric Company ("GE"). Key modifications include:
- Term Extension: The agreement term has been extended to January 14, 2021.
- Rights Modification: Certain rights of first offer held by GE regarding manufacturing and licensing rights for the Company's Thermo-Acoustic Enhanced Ultrasound technology (specifically for fatty liver disease applications) have been modified.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release issued on January 15, 2020, announcing the amendment. No specific financial guidance or forward-looking projections are included in this text.
Risks and Contingencies: The filing notes that the summary of the agreement is qualified in its entirety by reference to the full text of Amendment 3 (Exhibit 10.1). In the event of any conflict between the summary and the full text, the text of the Amendment controls.
Investor Verification Checklist
- Review Exhibit 10.1 (Amendment 3) to understand the specific details of the modified rights of first offer for GE.
- Verify the impact of the term extension to January 14, 2021, on the Company's future revenue recognition or milestone payments.
- Consult the press release dated January 15, 2020 (Exhibit 99.1) for additional management commentary not included in the 8-K summary.
- Confirm the status of the underlying Collaborative Research Agreement (originally dated April 22, 2016) and previous amendments to understand the full contractual history.